Cardiovascular Journal of Africa: Vol 31 No 5 (September/October 2020)

60 / 64

CARDIOVASCULAR JOURNAL OF AFRICA • Volume 31, No 5, September/October 2020 280 AFRICA
References
1. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic
syndrome: analysis of fourteen cases with review of the literature.
Medicine (Baltimore) 1975; 54: 1–27.
2. Wang SA. The diagnostic work-up of hypereosinophilia. Pathobiology
2019; 86: 39–52.
3. Wilkins HJ, Crane MM, Copeland K, Williams W. Hypereosinophilic
syndrome: An Update. Am J Hematol 2005; 80: 148–157.
4. Anderson RE, Hardy WR. Hypereosinophilia. Ann Intern Med 1968;
69: 1331–1332.
5. Mansour MJ, Rahal M, Chammas E, Hamoui O, Aljaroudi W. Cardiac
involvement in hypereosinophilic syndrome. Ann Pediatr Cardiol 2018;
11: 217–218.
6. Kleinfeldt T, Nienaber CA, Kische S, Akin I, Turan RG, Körber T, et al.
Cardiac manifestation of the hypereosinophilic syndrome: new insights.
Clin Res Cardiol 2010; 99: 419–427.
7. Brambatti M, Matassini MV, Adler ED, Klingel K, Camici PG,
Ammirati E. Eosinophilic myocarditis: characteristics, treatment, and
outcomes. J Am Coll Cardiol 2017; 70: 2363–2375.
8. Weissler JC. Eosinophilic lung disease. Am J Med Sci2017; 354: 339–349.
9. Freitas JG, Jorge A, Rei D1, Graça J. Ninety-year-old man with hypere-
osinophilia, lymphadenopathies and pruritus. Br Med J Case Rep 2018;
10; 2018.
10. Pozsonyi Z, Benedek S, Sármán P, Jánoskuti L, Hüttl T, Apor A.
Multiple valvular complications of hypereosinophilic syndrome. J Heart
Valve Dis 2016; 25: 752–755.
11. Zientek DM, King DL, Dewan SJ, Harford PH, Youman DJ, Hines TR.
Hypereosinophilic syndrome with rapid progression of cardiac involve-
ment and early echocardiographic abnormalities. Am Heart J 1995; 130:
1295–1298.
12. Butterfield JH, Kane GC, Weiler CR. Hypereosinophilic syndrome:
endomyocardial biopsy versus echocardiography to diagnose cardiac
involvement. Postgrad Med 2017; 129: 517–523.
13. Pillar N , Halkin A, Aviram G. Hypereosinophilic syndrome with cardiac
involvement: early diagnosis by cardiac magnetic resonance imaging. Can
J Cardiol 2012; 28: 515.
14. Porto AG, McAlindon E, Hamilton M, Manghat N, Bucciarelli-Ducci
C. Diagnosing cardiac involvement in the hypereosinophilic syndrome by
cardiac magnetic resonance. Am J Cardiol 2013; 112: 135–136.
15. Simon HU, Klion A. Therapeutic approaches to patients with hypere-
osinophilic syndromes. Semin Hematol 2012; 49: 160–170.
16. Dispenza MC, Bochner BS. Diagnosis and novel approaches to the treat-
ment of hypereosinophilic syndromes. Curr Hematol Malig Rep 2018;
13: 191–201.
17. Chandra M, Pettigrew RI, Eley JW, Oshinski JN, Guyton RA. Cine-
MRI-aided endomyocardectomy in idiopathic hypereosinophilic
syndrome. Ann Thorac Surg 1996; 62: 1856–1858.
18. Fang Q, Gu TX, Xiu ZY, Zhang ZW. Bioprosthetic valve replacement in
idiopathic hypereosinophilic syndrome with mitral valve involvement. J
Thorac Cardiovasc Surg 2013; 146: e45–47.
Trust the ! Original
S3 ISMO-20 R/7.1.4/136. Isosorbide-5-mononitrate 20 mg/tablet.
For full prescribing information, please refer to package insert.
Pharmaco Distribution (Pty) Ltd. 3 Sandown Valley Crescent, South Tower, 1st Floor, Sandton, 2196; PO Box 786522, Sandton, 2146, South Africa. Tel: + 27 11 784 0077.
Website:
1 Long-term prophylaxis and management of Angina Pectoris
2,3 = 100% bioavailability No first-pass metabolism
4 Twice daily dosage regimen shown to avoid withdrawal and tolerance
References: 1. South African approved ISMO package insert. 2. Ismo 20 Product Monograph (2015). 3. Abshagen, U., 1992. Pharmacokinetics of isosorbide mononitrate.
The American Journal of Cardiology,[online] 70(17), pp.G61-G66. 4. Thadani U, Maranda CR, Amsterdam E, et al. Lack of Pharmacological Tolerance and Rebound
Angina Pectoris during Twice-daily Therapy with Isosorbide-5-Mononitrate. Annals of Internal Medicine. 1994; 120:353-359. IS_0120.